<DOC>
	<DOC>NCT01028092</DOC>
	<brief_summary>This study is designed to evaluate efficacity and safety of everolimus or (cyclosporine then everolimus) vs. cyclosporine as immunosuppressive treatment in renal transplantation for elderly (&gt;60 years old) recipients receiving graft from elderly donor(&gt;60 years old).</brief_summary>
	<brief_title>mTor-inhibitor (EVERolimus) Based Immunosuppressive Strategies for CNI Minimisation in OLD for Old Renal Transplantation</brief_title>
	<detailed_description />
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Interleukin-2</mesh_term>
	<mesh_term>Immunosuppressive Agents</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<criteria>Patient who has given written informed consent to participate in the study First or second single transplantation of a recipient (male or female) older than 60 years old Donor older than 60 years old PRA &lt; 30% Living donor Third transplantation PRA &gt; 30% Other protocoldefined inclusion/exclusion criteria may apply. Recipient of multiorgan transplant Active major infections (HBV, HCV, HIV) Loss of a first graft for immunologic issues Anemia (&lt;9g/l) or leucopenia (&lt;2500/mm3)</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>